Dr. John Cush RheumNow
2 years 8 months ago
2022 ACR Classification Criteria for GCA: \ must be \>50yrs\ 6 points needed for #GCA AM stiff should/neck 2 Visual loss 3 Jaw Claud 2 Temp HA 2 Scalp tender 2 Hi ESR/CRP 3 Bx or US 5 axillary 2 PEG Aorta 2 https://t.co/LfkIZKnLZi https://t.co/LdQOoRfG5V
A new MSK syndrome of inflammatory enthesitis/arthritis/tenosynovitis has been described in atopic dermatitis (AD) patients treated with the IL-4 receptor antagonist, dupilumab.
The COLCHICORT trial in patients with acute calcium pyrophosphate crystal arthritis (CPPD) demonstrated equivalent efficacy for both colchicine and prednisone, yet different safety signals were seen.
Dr. John Cush RheumNow
2 years 8 months ago
RHEUMATOLOGIST SURVEY QUESTION: Is TYK2 part of the Janus Kinase family?
Click here to answer >> https://t.co/Uzad4Tp7YV
Dr. John Cush RheumNow
2 years 8 months ago
ICYMI: Effective Treatments for Rheumatoid Arthritis ILD
The ACR guidelines for the diagnosis and management of interstitial lung disease, which includes RA-ILD, has been one of the most controversial topics in the runup to ACR Convergence.
https://t.co/tvXEeaTbRq https://t.co/Dq3NcSAGhf
Dr. John Cush RheumNow
2 years 8 months ago
RheumNow Podcast – Bill of Rights
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow. Two major reports on fatigue and fibromyalgia misfired, and "ankylosing spondylitis" is sent to the Rheumatology dead word cemetery.
https://t.co/lYtunY4cqd https://t.co/yNPqhPx5y3
Dr. John Cush RheumNow
2 years 8 months ago
Gender Gap Confirmed for TNF Inhibitor Response in Axial SpA
Men with axial spondyloarthritis (axSpA) were more likely than women to obtain substantial relief with tumor necrosis factor (TNF) inhibitors, a multinational study indicated.
https://t.co/ye5iReGLMG https://t.co/goKe0TuYqz
Dr. John Cush RheumNow
2 years 8 months ago
Empathy is the hard part.
The rest is mechanics. We're not wired to walk in someone else's shoes, it's not our first instinct.
Showing up with empathy is difficult, hard to outsource and will wear you out. But it's precisely what we need from you. - Seth Godin… https://t.co/U8Ou3WwBmC https://t.co/C4aAVovHDH
Dr. John Cush RheumNow
2 years 8 months ago
SGLT2 inhibitor (empagliflozin) given in a lupus mouse (MRL/lpr) model showed a renoprotective effect suggesting the value of non-immunosuppressive therapies to improve renal function. Showed less -dsDNA Abs, proteinuria, renal nephritis damage https://t.co/VfLUbCjmMt https://t.co/EAsvfzRgm1
EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). AAV recommendations were last published in 2016, and since, research and clinical trials have advanced our understanding of AAV. A EULAR task force of 20 experts from 16 countries, reviewed the literature and developed four overarching principles and 17 recommendations.
This week I reached out to many leaders in rheumatology and asked: who are the great women in rheumatology who should be recognized? This was prompted by a smart article in Annals of Rheumatic Disease written by Drs. Tuhina Neogi (Boston) and Nicola Dalbeth (N. Zealand), entitled "Where are the women ‘Heroes and Pillars of Rheumatology’?
Dr. John Cush RheumNow
2 years 8 months ago
NVC in 1356 #SSc registry pts classified as early, active or‘late. Late pattern seen in 40%: signific. assoc w/ dcSSc (OR=1.96), ILD (OR=1.29), renal crisis (OR=3.46), digital ulcer (OR=1.29), & topoisomerase I Abs (OR=1.39) https://t.co/RgET0HbImf https://t.co/Ex3nKto6JW
